Prevention of cardiovascular disease guided by total risk estimations − challenges and opportunities for practical implementation: highlights of a CardioVascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
This paper presents a summary of the potential practical and economic barriers to implementation of primary prevention of cardiovascular disease guided by total cardiovascular risk estimations in the general population. It also reviews various possible solutions to overcome these barriers. The report is based on discussion among experts in the area at a special CardioVascular Clinical Trialists workshop organized by the European Society of Cardiology Working Group on Cardiovascular Pharmacology and Drug Therapy that took place in September 2009. It includes a review of the evidence in favour of the "treat-to-target" paradigm, as well as potential difficulties with this approach, including the multiple pathological processes present in high-risk patients that may not be adequately addressed by this strategy. The risk-guided therapy approach requires careful definitions of cardiovascular risk and consideration of clinical endpoints as well as the differences between trial and "real-world" populations. Cost-effectiveness presents another issue in scenarios of finite healthcare resources, as does the difficulty of documenting guideline uptake and effectiveness in the primary care setting, where early modification of risk factors may be more beneficial than later attempts to manage established disease. The key to guideline implementation is to improve the quality of risk assessment and demonstrate the association between risk factors, intervention, and reduced event rates. In the future, this may be made possible by means of automated data entry and various other measures. In conclusion, opportunities exist to increase guideline implementation in the primary care setting, with potential benefits for both the general population and healthcare resources.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598 · cited 1×
“The evidence on which these target values is based has recently been questioned.(2,18,19) In addition, and most importantly in both the hypertensive population and coronary hypertensive patients, BP control is only rarely achieved.”
BackgroundTelmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
(2003) · The Lancet · doi:10.1016/s0140-6736(03)14739-3 · Cited by 2,402 · cited 2×
“A recent meta-analysis of subjects assessed with intravascular ultrasound and treated with statins to LDL-C levels 1.81mmol/l ( 70mg/dl) showed that >20% of subjects continued to show evidence of plaque progression.13 This may be due to the fact that the atherogenic dyslipidaemia typically encountered in high-risk pat…”
BackgroundMosca, L., Benjamin, E. J., Berra, K., Bezanson, J. L., Dolor, R. J., Lloyd-Jones, D. M., Newby, L. K., Piña, I. L., Roger, V. L., Shaw, L. J., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31820faaf8 · Cited by 2,143
Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., Grassi, G., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3282f0580f · Cited by 1,837
Self-citationMancia, G., Laurent, S., Agabiti-Rosei, E., Ambrosioni, E., Burnier, M., Caulfield, M. J., Cifkova, R., Clément, D., Coca, A., Dominiczak, A., et al. (2009) · Journal of Hypertension · doi:10.1097/hjh.0b013e328333146d · Cited by 1,643
Self-citationChapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Angiotensin-converting-enzyme inhibition in stable coronary artery disease
(2004) · New England Journal of Medicine · doi:10.1056/nejmoa042739 · Cited by 1,123
(2008) · The Lancet · doi:10.1016/s0140-6736(08)61242-8 · Cited by 1,000 · cited 1×
“These studies include, for example, the Heart Outcomes Prevention Evaluation trial (HOPE),(35) the EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease (EUROPA),(36) the Prevention of Events with ACE inhibition (PEACE) trial,(37) the ONgoing Telmisartan Alone and in combinat…”
MethodKotseva, K., Wood, D., De Backer, G., De Bacquer, D., Pyörälä, K., & Keil, U. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60330-5 · Cited by 833
Piepoli, M. F., Corrà, U., Benzer, W., Bjarnason-Wehrens, B., Dendale, P., Gaita, D., McGee, H., Mendes, M., Niebauer, J., Zwisler, A.-D. O., et al. (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283313592 · Cited by 796 · cited 1×
“European guidelines for the secondary prevention of CVD by means of cardiac rehabilitation have also been published recently.(10) Nevertheless, there remain a number of issues that may prevent the practical use of risk-guided therapy that may otherwise allow us to optimize the benefit-to-risk ratio in a population wit…”
BackgroundMeta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy
Cannon, C. P., Steinberg, B. A., Murphy, S. A., Mega, J. L., & Braunwald, E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.04.070 · Cited by 770
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706
Self-citationMancia, G., Facchetti, R., Bombelli, M., Grassi, G., & Sega, R. (2006) · Hypertension · doi:10.1161/01.hyp.0000215363.69793.bb · Cited by 691 · cited 1×
“to identify patients at goal, presumably because 30–40% of hypertensive patients may have white-coat hypertension and thus a normal ambulatory blood pressure from the start.(26) Patients may also vary in their ability to tolerate low BP, depending on the extent of end-organ disease present.”
BackgroundSelf-citationA systematic review and economic evaluation of statins for the prevention of coronary events
Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N. (2007) · Health Technology Assessment · doi:10.3310/hta11140 · Cited by 556 · cited 1×
“Nevertheless, there is compelling evidence that treating high-risk subjects with efficient preventive measures is cost-effective.(49) Table 1.”
BackgroundRollnick, S., Butler, C. C., Kinnersley, P., Gregory, J., & Mash, B. (2010) · BMJ · doi:10.1136/bmj.c1900 · Cited by 379
Banegas, J. R., Lopez-Garcia, E., Dallongeville, J., Guallar, E., Halcox, J. P., Borghi, C., Masso-Gonzalez, E. L., Jimenez, F. J., Perk, J., Steg, P. G., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr080 · Cited by 354 · cited 1×
“Recent evidence from the population surveys also demonstrated underachievement of guideline targets in a substantial proportion of patients with stable atherothrombotic disease.(56) These data do not necessarily indicate that individualized assessments are not being completed, only that the process is not being docume…”
BackgroundSelf-citationFruchart, J.-C., Sacks, F. M., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.046 · Cited by 260 · cited 1×
“This may be due to the fact that the atherogenic dyslipidaemia typically encountered in high-risk patients with metabolic disorders, such as diabetes, metabolic syndrome, and/or obesity, is often characterized by elevated triglycerides and low highdensity lipoprotein cholesterol (HDL-C), which may not be efficaciously…”
BackgroundKotseva, K., Wood, D., De Backer, G., De Bacquer, D., Pyörälä, K., Reiner, Ž., Keil, U., & EUROASPIRE Study Group (2010) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283383f30 · Cited by 238
Self-citationTelehealthcare for long term conditions
McLean, S., Protti, D., & Sheikh, A. (2011) · BMJ · doi:10.1136/bmj.d120 · Cited by 205 · cited 1×
“In this respect, ‘telehealthcare’ via the internet and smart phones represents an increasingly important channel of contact and follow-up for the management of long-term conditions.(71) One example is PREDICT-CVD, a web-based decision support system for primary care patients in New Zealand.”
BackgroundReiner, Ž., Sonicki, Z., & Tedeschi-Reiner, E. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.09.014 · Cited by 148 · cited 1×
“That is, although most physicians support the use of guidelines, according to recent data, only half actually use them in their everyday work, and their level of knowledge of target goals is less than satisfactory.(51) Furthermore, while 80% of physicians believe they are treating their dyslipidaemic patients well, ov…”
ResultSelf-citationAdding The Patient Perspective To Comparative Effectiveness Research
Wu, A. W., Snyder, C., Clancy, C. M., & Steinwachs, D. M. (2010) · Health Affairs · doi:10.1377/hlthaff.2010.0660 · Cited by 147
Graham, I. M., Stewart, M., Hertog, M. G. L., & Forced, O. B. O. T. C. R. T. T. (2006) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/01.hjr.0000219112.02544.24 · Cited by 116
Self-citationWells, S., Furness, S., Rafter, N., Horn, E., Whittaker, R., Stewart, A., Moodabe, K., Roseman, P., Selak, V., Bramley, D., et al. (2008) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3282f13af4 · Cited by 109
Public perceptions of cardiovascular risk factors in Croatia: The PERCRO survey
Reiner, Ž., Sonicki, Z., & Tedeschi-Reiner, E. (2010) · Preventive Medicine · doi:10.1016/j.ypmed.2010.09.015 · Cited by 73
Self-citation
Cited by
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Cicero, A. F. G., Fogacci, F., & Colletti, A. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13608 · Cited by 317
Prevention of stroke: a strategic global imperative
Feigin, V. L., Norrving, B., George, M. G., Foltz, J. L., Roth, G. A., & Mensah, G. A. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.107 · Cited by 250
Reiner, Ž. (2013) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2013.05.002 · Cited by 147
Self-citationPrimary prevention of cardiovascular disease with statins in the elderly
Reiner, Ž. (2014) · Current Atherosclerosis Reports · doi:10.1007/s11883-014-0420-6 · Cited by 38
Self-citation
Metadata
- Authors
- Zannad, F., Dallongeville, J., Macfadyen, R. J., Ruilope, L. M., Wilhelmsen, L., De Backer, G., Graham, I., Lorenz, M., Mancia, G., Morrow, D. A., Reiner, Ž., & Koenig, W.
- Venue
- European Journal of Preventive Cardiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-09-26
- Volume
- 19
- Issue
- 6
- Pages
- 1454-1464
- ISSN
- 2047-4873 (ISSN-L)
- 2047-4881
- OpenAlex
- W2112936129
- Cited by
- 28
- References
- 27
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.